Regeneron Pharmaceuticals Inc.

74 trials 25 recruiting Commercial sponsor

Filter these 74 trials by condition, phase, country and more.

Open in Search →

74 Registered trials

25 Recruiting

33 Completed trials

18 Countries active

73 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (FiH)

Phase III: 23 Phase II/III: 2 Phase II: 17 Phase I/II: 1 Phase IV: 1 Phase I: 16 Phase I (Other): 4 Phase I (FiH): 10

Oversight events:

1 serious breach 3 temporary halts 2 corrective measures across 4 trials

View oversight register →

100%

33 of 33 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 7 Malignant melanoma 3 Diffuse large B-cell lymphoma 3 Non-Hodgkin's lymphoma unspecified histology aggressive recurrent 2 Follicle centre lymphoma follicular grade I II III 2 Peritoneal cancer index 2 Hereditary angioedema 2 Ovarian cancer recurrent 2 Fallopian tube cancer 2 Eosinophilic gastritis 1 Follicular lymphoma 1 Iron overload 1

Top IMPs

CEMIPLIMAB 16 LINVOSELTAMAB 7 DEXAMETHASONE 5 DIPHENHYDRAMINE HYDROCHLORIDE 5 FIANLIMAB 5 ODRONEXTAMAB 5 PARACETAMOL 5 REGN7508 5 CARBOPLATIN 4 CEMDISIRAN 4 CISPLATIN 4 DEXAMETHASONE SODIUM PHOSPHATE 4

All trials — page 4

74 total

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload … Ended

2023-508604-37-00 Phase II 2 countries REGN7999
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Aller… Ended

2024-511032-27-00 Phase I (Other) 1 country

Showing 73–74 of 74 trials

← All sponsors A–Z